Apellis Pharmaceuticals, Inc. (APLS) News

Apellis Pharmaceuticals, Inc. (APLS): $60.37

-0.67 (-1.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter APLS News Items

APLS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

APLS News Highlights

  • For APLS, its 30 day story count is now at 7.
  • Over the past 23 days, the trend for APLS's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • LI, NGM and DRUG are the most mentioned tickers in articles about APLS.

Latest APLS News From Around the Web

Below are the latest news stories about APELLIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate APLS as an investment opportunity.

Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting

New analyses of microperimetry data showed positive trends with both monthly and every-other-month pegcetacoplan treatment near the GA lesion border compared to shamThese analyses provide further evidence that slowing GA lesion growth with pegcetacoplan has the potential to preserve visual functionData were presented during an oral presentation at the American Academy of Ophthalmology Annual Meeting WALTHAM, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS),

Yahoo | September 30, 2022

Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting

WALTHAM, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that four oral presentations of data from the Phase 3 DERBY and OAKS studies evaluating pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration will be presented at the American Academy of Ophthalmology (AAO) Annual Meeting on September 30 – October 3 in Chicago, Illinois. Dat

Yahoo | September 30, 2022

Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference

WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced updated timing for its fireside chat at an upcoming investor conference hosted by Bank of America. Updated Conference Details Bank of America Global Healthcare Conference: Fireside chat on Friday, September 16, 2022 at 9:55 a.m. BST / 4:55 a.m. ET. The conference events will be available via a live webcast from the “Events a

Yahoo | September 12, 2022

Apellis (APLS) Up More Than 60% in Past 3 Months: Here's Why

Apellis' (APLS) marketed drug, Empaveli, approved for treating paroxysmal nocturnal hemoglobinuria is driving revenues. The drug's label expansion studies also hold promise.

Yahoo | September 9, 2022

Apellis gains as FDA says AdCom unnecessary for eye disease candidate

  • The commercial-stage biotech Apellis Pharmaceuticals (NASDAQ:APLSadded ~10% Wednesday amid comments attributed to its Chief Executive, who said that FDA would not conduct an AdCom meeting to decide on the marketing application for its lead asset pegcetacoplan.
  • The New Drug Application (NDA) for the intravitreal medication is currently under the FDA’s priority review as a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) with a target action date on Nov. 26.
  • At the Citi BioPharma Conference, APLS C...

    Seeking Alpha | September 7, 2022

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to 64 new employees with a grant date of September 1, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the comp

Yahoo | September 7, 2022

Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 9.8% Since Last Earnings Report?

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 7, 2022

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences in September: Citi 17th Annual BioPharma Conference: Fireside chat on Wednesday, September 7, 2022 at 1:00 p.m. ET.Wells Fargo Healthcare Conference: Fireside chat on Thursday, September 8, 2022 at 1:55 p.m. ET.Baird 2022 Global Healthcare Conference: Pr

Yahoo | September 1, 2022

Analysts Offer Insights on Healthcare Companies: AC Immune SA (ACIU) and Apellis Pharmaceuticals (APLS)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AC Immune SA (ACIU – Research Report) and Apellis Pharmaceuticals (APLS – Research Report) with bullish sentiments. AC Immune SA (ACIU) In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on AC Immune SA, with a price target of $16.00. The company's shares closed last Wednesday at $3.52, close to its 52-week low of $2.06. According to TipRanks.

Brian Anderson on TipRanks | August 25, 2022

Needham Remains a Buy on Apellis Pharmaceuticals (APLS)

In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Apellis Pharmaceuticals (APLS - Research Report), with a price target of $70.00. The company's shares opened today at $64.85.Stringer covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Alnylam Pharma, and Lexicon Pharmaceuticals. According to TipRanks, Stringer has an average return of 3.3% and a 45.93% success rate on recommended stocks. In addition to Needham, Apellis Pharmaceuticals also received a Buy from Oppenheimer's Justin Kim in a report issued on August 18. However, on August 9, Roth Capital reiterated a Sell rating on Apellis Pharmaceuticals (NASDAQ: APLS).

Ryan Adist on TipRanks | August 24, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6277 seconds.